Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
Ling Liu,1 Jirong Lu,1 Barrett W Allan,2 Ying Tang,2 Jonathan Tetreault,1 Chi-kin Chow,1 Barbra Barmettler,2 James Nelson,2 Holly Bina,1 Lihua Huang,3 Victor J Wroblewski,4 Kristine Kikly1 1Biotechnology Discovery Research, Indianapolis, IN, 2Applied Molecular Evolution, Lilly Biotechnology...
Main Authors: | Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow C, Barmettler B, Nelson J, Bina H, Huang L, Wroblewski VJ, Kikly K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Journal of Inflammation Research |
Subjects: | |
Online Access: | https://www.dovepress.com/generation-and-characterization-of-ixekizumab-a-humanized-monoclonal-a-peer-reviewed-article-JIR |
Similar Items
-
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01) -
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01) -
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
by: Gil Yosipovitch, et al.
Published: (2018-11-01) -
Pyoderma gangrenosum in a patient on ixekizumab
by: Ilana R. Pollack, MSc, et al.
Published: (2021-10-01) -
Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)